NCT05396833
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05396833
Title Study of M1774 in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors EMD Serono Research & Development Institute, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP | CAN | AUS


No variant requirements are available.